Printer-friendly format

One area of research at The Endocrine Clinic involves inhaled insulin therapies that prevent patients from having to inject insulin. Below are the newest inhibitors which will be studied further at the clinic:

EXUBERA® – Newly released in the United States, this is one of the first inhaled insulin products recently made available to patients. Manufactured by Pfizer, the inhalation powder can be used to treat type 1 and type 2 diabetes.

Galvus® – new oral therapy developed by Novartis, Galvus is a DPP-4 inhibitor developed to help treat type 2 diabetes. A clinical trial is set to begin at The Endocrine Clinic in the next few months.

Januvia™ – On October 17, the FDA approved the first and only DPP-4 inhibitor now available on the United States market for treating type 2 diabetes. A prescription medication, JANUVIA is an inhibitor that works with the incretin system to help regulate glucose.



November 2006

Tags:

None